Structural Substrate Conditions Required for Neutral Endopeptidase-Mediated Natriuretic Peptide Degradation

Journal of Molecular Biology

Volumn 393, Issue 2, 2009, Pages 496-503

  Pankow, Kristin ^a,b   Schwiebs, Anja ^c   Becker, Matthias ^b   Siems, Wolf Eberhard ^b   Krause, Gerd ^b   Walther, Thomas ^c,d  

^a Fachbereich Biologie   (Germany)

^b LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^c UNIVERSITY OF HULL   (United Kingdom)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

B type natriuretic peptide; catalytic site; natriuretic peptides; neutral endopeptidase; truncated peptides

Indexed keywords

MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC FACTOR; RECOMBINANT PROTEIN; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT;

AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN HEK293; CONTROLLED STUDY; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN CELL; KIDNEY PARENCHYMA; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SEQUENCE ALIGNMENT; ANIMAL; CELL LINE; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; PROTEIN BINDING;

ANIMALS; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MICE; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES; NEPRILYSIN; PEPTIDE FRAGMENTS; PROTEIN BINDING;

EID: 70349425660     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.08.025     Document Type: Article

References (23)

1. de Bold A.J., Borenstein H.B., Veress A.T., and Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 28 (1981) 89-94
2. Sudoh T., Kangawa K., Minamino N., and Matsuo H. A new natriuretic peptide in porcine brain. Nature 332 (1988) 78-81
3. Sudoh T., Minamino N., Kangawa K., and Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem. Biophys. Res. Commun. 168 (1990) 863-870
4. Suga S.-I., Nakao K., Itoh H., Komatsu Y., Ogawa Y., Hama N., and Imura H. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth-factor-β. Possible existence of vascular natriuretic peptide system. J. Clin. Invest. 90 (1992) 1145-1149
5. Schulz-Knappe P., Forssmann K., Herbst F., Hock D., Pipkorn R., and Forssmann W.-G. Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin. Wochenschr. 66 (1988) 752-759
6. Schweitz H., Vigne P., Moinier D., Frelin C., and Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J. Biol. Chem. 267 (1992) 13928-13932
7. Kenny A.J., Bourne A., and Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilation, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem. J. 291 (1993) 83-88
8. Kenny A.J., and Stephenson S.L. Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide. FEBS Lett. 232 (1988) 1-8
9. Walther T., Stepan H., Pankow K., Becker M., Schultheiss H.-P., and Siems W.-E. Biochemical analysis of neutral endopeptidase activity reveals independent catabolism of atrial and brain natriuretic peptide. Biol. Chem. 385 (2004) 179-184
10. Pankow K., Wang Y., Gembardt F., Krause E., Sun X., Krause G., et al. Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ. Res. 101 (2007) 875-882
11. Oefner C., D'Arcy A., Hennig M., Winkler F.K., and Dale G.E. Structure of human neutral endopeptidase (neprilysin) complexed with phosphoramidon. J. Mol. Biol. 296 (2000) 341-349
12. Oefner C., Pierau S., Schulz H., and Dale G.E. Structural studies of a bifunctional inhibitor of neprilysin and DPP-IV. Acta Crystallogr., Sect. D: Biol. Crystallogr. 63 (2007) 975-981
13. Oefner C., Roques B.P., Fournie-Zaluski M.-C., and Dale G.E. Structural analysis of neprilysin with various specific and potent inhibitors. Acta Crystallogr., Sect. D: Biol. Crystallogr. 60 (2004) 392-396
14. Carpenter K.A., Wilkes B.C., De Léan A., Fournier A., and Schiller P.W. Hydrophobic forces are responsible for the folding of a highly potent natriuretic peptide analogue at a membrane mimetic surface: an NMR study. Biopolymers 42 (1997) 37-48
15. Fairbrother W.J., McDowell R.S., and Cunningham B.C. Solution conformation of an atrial natriuretic peptide variant selective for the type A receptor. Biochemistry 33 (1994) 8897-8904
16. He X.-L., Dukkipati A., and Garcia K.C. Structural determinants of natriuretic peptide receptor specificity and degeneracy. J. Mol. Biol. 361 (2006) 698-714
17. Brandt I., Lambeir A.-M., Ketelslegers J.-M., Vanderheyden M., Scharpe S., and De Meester I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin. Chem. 52 (2006) 82-87
18. Shimizu H., Masuta K., Aono K., Asada H., Sasakura K., Tamaki M., et al. Molecular forms of human brain natriuretic peptide in plasma. Clin. Chim. Acta 316 (2002) 129-135
19. Gagelmann M., Hock D., and Forssmann W.G. Urodilatin (CDD/ANP-95-126) is not biologically inactivated by a peptidase from dog kidney cortex membranes in contrast to atrial natriuretic peptide/cardiodilatin (α-hANP/CDD-99-126). FEBS Lett. 233 (1988) 249-254
20. Daull P., Jeng A.Y., and Battistini B. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases. J. Cardiovasc. Pharmacol. 50 (2007) 247-256
21. Iwata N., Tsubuki S., Takaki Y., Watanabe K., Sekiguchi M., Hosoki E., et al. Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6 (2000) 143-150
22. Arbin V., Claperon N., Fournie-Zaluski M.C., Roques B.P., and Peyroux J. Effects of dual angiotensin-converting enzyme and neutral endopeptidase 24-11 chronic inhibition by mixanpril on insulin sensitivity in lean and obese Zucker rats. J. Cardiovasc. Pharmacol. 41 (2003) 254-264
23. Wei C.M., Kim C.H., Miller V.M., and Burnett Jr. J.C. Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J. Clin. Invest. 92 (1993) 2048-2052